For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.